Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating reiterated by Guggenheim in a research note issued to investors on Tuesday,Benzinga reports.
Other equities research analysts also recently issued research reports about the stock. Jefferies Financial Group boosted their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Monday, April 21st. HC Wainwright reiterated a "buy" rating and set a $24.00 price target on shares of Compass Therapeutics in a research report on Monday, April 21st. Leerink Partners upgraded Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Finally, Piper Sandler started coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Compass Therapeutics currently has an average rating of "Buy" and a consensus price target of $13.38.
Read Our Latest Stock Analysis on Compass Therapeutics
Compass Therapeutics Stock Down 8.5 %
NASDAQ:CMPX traded down $0.18 during trading hours on Tuesday, reaching $1.94. 877,992 shares of the stock were exchanged, compared to its average volume of 877,620. The stock has a market capitalization of $268.27 million, a P/E ratio of -5.24 and a beta of 1.40. The firm has a 50 day simple moving average of $2.23 and a 200-day simple moving average of $2.10. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.
Insiders Place Their Bets
In related news, insider Jonathan Anderman purchased 20,000 shares of the company's stock in a transaction on Monday, April 7th. The shares were bought at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the transaction, the insider now owns 21,000 shares of the company's stock, valued at $32,340. This represents a 2,000.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Compass Therapeutics
Several hedge funds have recently modified their holdings of the company. Barclays PLC boosted its stake in Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company's stock valued at $314,000 after buying an additional 112,614 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company's stock valued at $4,251,000 after purchasing an additional 19,095 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock worth $573,000 after purchasing an additional 356,352 shares during the last quarter. Catalina Capital Group LLC bought a new stake in shares of Compass Therapeutics in the 4th quarter worth approximately $71,000. Finally, Bleakley Financial Group LLC lifted its stake in Compass Therapeutics by 250.7% during the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company's stock valued at $58,000 after purchasing an additional 28,589 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.
About Compass Therapeutics
(
Get Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Featured Articles
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
